Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
CAR T-cell therapy is a promising treatment for some patients with non-Hodgkin lymphoma (NHL) that has relapsed or has not responded to other therapies (refractory). It is a highly-specialized therapy that involves genetically modifying a patient's own T cells to attack their cancer. The FDA has approved several CAR T-cell therapies for lymphoma. Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) is one of the first centers to make the FDA-approved CAR T-cell therapies available as standard of care to patients who have not had effective treatment options. CAR T-cell therapies are FDA approved for:
Aggressive relapsed or refractory large B-cell lymphoma including diffuse large B cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, and transformed follicular lymphoma.
Relapsed or refractory mantle cell lymphoma
Relapsed or refractory follicular lymphoma
Our program also offers patients clinical trials of CAR T-cell therapy for other forms of lymphoma as well as trials of CAR T-cell therapy earlier in treatment
and in combination with other immunotherapies.
Patients are evaluated carefully to determine if this therapy is appropriate for them. Learn more about CAR T-cell therapy.
Caron Jacobson, MD, detailed the research that led to FDA approval of CAR T-cell therapy for mantle cell lymphoma in July 2020.
Contact Information for CAR T-Cell Therapy
For more information about CAR T-cell therapy, please call 877-801-CART (2278).
Pediatric CAR T-Cell Therapy
Dana-Farber/Boston Children's is a certified treatment center for providing the recently FDA-approved CAR T-cell therapy called KYMRIAH to patients who are up to 25 years old with second or later relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).
Caron Jacobson, MD, Medical Director of the Immune Effector Cell Therapy program, discussed the first approval of chimeric antigen receptor (CAR) T-cell therapy for certain patients with non-Hodgkin lymphoma in October 2017.